Vicore Pharma announces completion of patient enrollment in the COVID-19 ATTRACT trial
Gothenburg, October 1, 2020 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces that the last patient has been randomized in the ATTRACT COVID-19 VP01 trial.The last patient in the ATTRACT (Angiotensin II Type Two Receptor Agonist Covid-19 Trial) study has now been randomized and will be treated for up to one week and then followed up for another week. Thereafter, the data is quality controlled and the database will be locked before the study is unblinded for analysis. Top-line results are expected